文献速递膀胱癌与上尿路尿路上皮癌

泌尿系统肿瘤:新型免疫治疗药物在非肌层浸润性膀胱癌管理中的叙事综述

Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease.
PubMed 文献 · BJU Int · 2019-01-22

本文为叙事综述,回顾非肌层浸润性膀胱癌(NMIBC)的治疗指南、免疫检查点抑制原理及尿路上皮恶性肿瘤中检查点抑制剂的证据。综述指出TURBT术后辅助治疗进展有限,现有膀胱内治疗复发率高且副作用显著,正在进行的试验将指导NMIBC未来治疗。

要点

  • 高危NMIBC的标准治疗为膀胱内BCG免疫治疗,但副作用和失败率显著。
  • 免疫检查点抑制剂已获批用于晚期尿路上皮癌,NMIBC相关试验正在进行中。
  • TURBT术后辅助治疗进展有限,现有膀胱内治疗复发率高。

核心结论

  • TURBT治疗的NMIBC辅助治疗进展有限,当前膀胱内治疗复发率高且副作用显著。
  • 正在进行的检查点抑制相关试验将指导NMIBC的未来治疗。

研究设计与样本

  • 叙事综述,检索PubMed/Medline(1966年至2017年9月)以「bladder cancer」和「checkpoint inhibitors」为检索词。
  • 另检索clinicaltrials.gov以「non-muscle-invasive bladder cancer」查找未发表的在研试验。

主要发现

  • 系统免疫治疗已在晚期尿路上皮恶性肿瘤中显示成功应用,尤其免疫检查点抑制剂。
  • 部分检查点抑制剂已获英国NICE和美国FDA批准。
  • 膀胱内BCG免疫治疗是高危NMIBC数十年来的主要治疗,但副作用和失败率显著。

临床怎么用

  • 了解NMIBC当前指南治疗及免疫检查点抑制原理。
  • 关注检查点抑制剂在NMIBC中的在研试验证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This narrative review describes current guidelines for treating NMIBC, provides an overview of the principle behind immune checkpoint inhibition, and summarizes current evidence for checkpoint inhibitors in urothelial malignancy. Further, we discuss potential strategies for immune checkpoint inhibition in the management of NMIBC. BACKGROUND: Adjuvant intravesical BCG immunotherapy has been the mainstay of treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) for decades but is associated with both a significant side effect profile and failure rate. Recently, a substantial body of trial data has been published demonstrating the successful use of systemic immunotherapy in the treatment of advanced urothelial malignancy and, in particular, a class of drugs known as 'immune checkpoint inhibitors'. This has led to the approval of a number of these drugs by the UK National Institute of Health and Care Excellence and the US Food and Drug Administration, and ongoing trials are examining use in the management of NMIBC. METHODS: To identify relevant published data, using the PubMed/ Medline search engine, an online search of the Pubmed/ Medline archives was conducted using the terms bladder cancer' in combination with 'checkpoint inhibitors', and limited to articles in English published between 1966 and September 2017.To identify ongoing trials of interest but not yet published, a further search of the clinical trials.gov search engine was conducted using the term 'non-muscle-invasive bladder cancer'. CONCLUSION: There has been little advance in available adjuvant therapy for NMIBC treated with TURBT. Current intravesical therapies are associated with a high recurrence rate and significant side effect profile. The impending publication of the wealth of ongoing trials, both into the delivery and efficacy of checkpoint inhibition will direct the future treatment of NMIBC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Doyle E, Crew J, Mostafid H, et al. Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. BJU Int. 2019. PMID: 30548196. doi:10.1111/bju.14643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。